<DOC>
	<DOCNO>NCT02875262</DOCNO>
	<brief_summary>Aneurysmal subarachnoid hemorrhage ( SAH ) form stroke secondary neurological deterioration important cause mortality morbidity . These secondary change , call delayed cerebral ischemia ( DCI ) , cause lysis erythrocyte react form iron , toxic substance brain . Iron chelators remove excess iron standard care iron-overloaded patient . Deferoxamine ( DFO ) chelator evaluate SAH patient . This study evaluate safety deferoxamine SAH patient</brief_summary>
	<brief_title>Deferoxamine Aneurysmal Subarachnoid Hemorrhage Trial</brief_title>
	<detailed_description>Aneurysmal subarachnoid hemorrhage ( SAH ) devastate form stroke affect relatively young patient . It incidence 7 per 100,000 . Associated economic cost high . Treatment aneurysm prevent rebleeding primary goal . Nevertheless , 3 12 day initial bleed secondary ischemic change occur 30 % patient . This delayed cerebral ischemia ( DCI ) remain important cause mortality morbidity patient survive aneurysm treatment . Aneurysmal SAH expose brain erythrocyte . Several day hemorrhage lysis erythrocyte take place brain expose high concentration hemoglobin . Elevated hemoglobin concentration present basal surface brain , also distribute around brain deep layer cortex . Heme degrade heme-oxygenase carbon monoxide , biliverdin iron . Free iron react H2O O2- form hydroxyl radical ( OH* ) . The generation hydroxyl radical cascade , know Haber-Weiss Fenton reaction , lead extraction hydrogen unsaturated lipid cell membrane initiate lipid peroxidation . Additionally exacerbate excitotoxicity increase intracellular iron accumulation . Iron chelators remove excess iron standard care iron-overloaded patient . The use iron chelators SAH subject animal study promise result reduce vasospasm , oxidative stress , neuronal cell death mortality . No clinical study use deferoxamine aneurysmal subarachnoid hemorrhage perform . A safety study use Deferoxamine patient intracerebral hemorrhage ( distinct subarachnoid hemorrhage ) perform . There associate serious adverse event mortality , Deferoxamine chelator use 40 year patient iron overload disease . This study investigate safety tolerability deferoxamine versus placebo patient SAH 3 consecutive day .</detailed_description>
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Subarachnoid Hemorrhage</mesh_term>
	<mesh_term>Intracranial Aneurysm</mesh_term>
	<mesh_term>Deferoxamine</mesh_term>
	<criteria>subarachnoid hemorrhage diagnose CT admission , Randomizable within 72 hour subarachnoid hemorrhage , Saccular intracranial aneurysm proven cerebral angiography CTA , Surgical endovascular obliteration perform , Able obtain write informed consent patient surrogate . Patients good clinical grade ( WFNS 13 ) Pregnancy , confirm routine urine test admission , Abnormal renal function time randomization ( GFR &lt; 60 mL/min ) Elevated liver function test time randomization ( AST &gt; 45 U/L ALT &gt; 35 U/L . ) History liver disease active liver disease , Active renal disease , Hypersensitivity deferoxamine , Patient take medication recommend concomitant use deferoxamine per product label ( e.g . high dose vit . C medication ) . Patients able complete study followup presence 4 follow exclusion criterion ( risk modifier ARDS ) : Tachypnea ( respiratory rate &gt; 30 ) SpO2 &lt; 95 % Obesity ( BMI &gt; 30 ) Acidosis ( pH &lt; 7.35 ) Hypoalbuminemia ( albumin &lt; 3.5 g/dL ) concurrent use chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>intracranial aneurysm</keyword>
	<keyword>subarachnoid hemorrhage</keyword>
	<keyword>stroke</keyword>
	<keyword>chelator</keyword>
</DOC>